⌕
Alnylam Pharmaceuticals · ALNY · Nasdaq
Tenet 51 · Mixed
Compare
$165.04+5.36%At closeTenet 51 · Mixed
$165.04+8.39 (+5.36%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Alnylam Pharmaceuticals (ALNY) Stock

Alnylam Pharmaceuticals (ALNY) closed at $165.04 on Nov 13, 2026; its Tenet Score is 51 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

12 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$165.04
Nov 13, 2026
Market cap
$22.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
70.8×
price ÷ earnings
52-week range
149.18 – 479.79
low → high · as of close, Nov 13, 2026
Tenet Score
51/100
Mixed · 313 Healthcare peers

Industry: Drugs

Alnylam Pharmaceuticals Inc scores 51/100. Mixed. Strongest on growth and quality, value is the soft spot, trading at 71× earnings versus 313 Healthcare peers.

Tenet Score · vs sector

n=313
51/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
16
Quality
71
Health
44
Growth
75

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityBHealthDGrowthBMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
28.0×
price to book value
P/S
6.0×
price to sales
ROE
73%
return on equity
Operating margin
13.5%
before interest and tax
Net margin
8.4%
of revenue kept
Current ratio
2.76
current assets to liabilities
Net debt / EBITDA
−3.4×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic med…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 251 US ETFs · top wrappers by weightSee all ETFs holding ALNY →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

Compare Alnylam Pharmaceuticals with

What sector and industry is Alnylam Pharmaceuticals in?

Alnylam Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Alnylam Pharmaceuticals' Tenet Score?

Alnylam Pharmaceuticals' Tenet Score is 51 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.